Studies of Benzamide‐ and Thiol‐Based Histone Deacetylase Inhibitors in Models of Oxidative‐Stress‐Induced Neuronal Death: Identification of Some HDAC3‐Selective Inhibitors
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Less stress: We compare three structurally different classes of histone deacetylase (HDAC) inhibitors that contain benzamide, hydroxamate, or thiol groups as the zinc binding group (ZBG) for their ability to protect cortical neurons in culture from cell death induced by oxidative stress. Novel benzamide‐based ligands selectively inhibit HDAC3 but provide no neuroprotection in the HCA–cortical neuron model of oxidative stress.magnified image We compare three structurally different classes of histone deacetylase (HDAC) inhibitors that contain benzamide, hydroxamate, or thiol groups as the zinc binding group (ZBG) for their ability to protect cortical neurons in culture from cell death induced by oxidative stress. This study reveals that none of the benzamide‐based HDAC inhibitors (HDACIs) provides any neuroprotection whatsoever, in distinct contrast to HDACIs that contain other ZBGs. Some of the sulfur‐containing HDACIs, namely the thiols, thioesters, and disulfides present modest neuroprotective activity but show toxicity at higher concentrations. Taken together, these data demonstrate that the HDAC6‐selective mercaptoacetamides that were reported previously provide the best protection in the homocysteic acid model of oxidative stress, thus further supporting their study in animal models of neurodegenerative diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For this reason, RGFP966 (Figure 11) has emerged as the most frequently employed tool for HDAC3 pharmacologic inhibition in biological studies [9, 13, 67, 69–71].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [71]
Citations
Cites
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Murphy, T. H., Miyamoto, M., Sastre, A., Schnaar, R. L., & Coyle, J. T. (1989) · Neuron · doi:10.1016/0896-6273(89)90043-3 · Cited by 1,029
(2002) · PubMed · Cited by 732
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Rapid Communication: Oxidative Stress Induces Apoptosis in Embryonic Cortical Neurons
Ratan, R. R., Murphy, T. H., & Baraban, J. M. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010376.x · Cited by 584
Kim, H. J., Rowe, M., Ren, M., Hong, J.-S., Chen, P.-S., & Chuang, D.-M. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120188 · Cited by 557
Research works printed but not linked: 2
- Kelly W. K., 2003, Clin. Cancer Res., 9, 3578
- Furumai R., 2002, Cancer Res., 62, 4916
Cited by
Shen, S., & Kozikowski, A. P. (2016) · ChemMedChem · doi:10.1002/cmdc.201500486 · Cited by 288
Self-citationTherapeutic potential for HDAC inhibitors in the heart
McKinsey, T. A. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134712 · Cited by 230
“Another study reported rapid induction of HDAC3 catalytic activity in neonatal rat ventricular myocytes (NRVMs) treated with lipopolysaccharide (LPS) (79).”
BackgroundInfluentialDevelopment and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
Kalin, J. H., & Bergman, J. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001659 · Cited by 126
Protein Acetylation in the Cardiorenal Axis: The Promise of Histone Deacetylase Inhibitors
Bush, E. W., & McKinsey, T. A. (2010) · Circulation Research · doi:10.1161/circresaha.109.209338 · Cited by 121
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Suzuki, T., Kasuya, Y., Itoh, Y., Ota, Y., Zhan, P., Asamitsu, K., Nakagawa, H., Okamoto, T., & Miyata, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068669 · Cited by 101
Lanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 112
Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart
McKinsey, T. A. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.11.009 · Cited by 108
Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases
Wagner, F. F., Weïwer, M., Lewis, M. C., & Holson, E. B. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0226-1 · Cited by 107
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Sangwan, R., Rajan, R., & Mandal, P. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.073 · Cited by 98
Adhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.081 · Cited by 74
Wagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y.-L., Chattopadhyay, S., Gale, J. P., Galbo, T., Fisher, S. L., Meier, B. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00640 · Cited by 86
Schmitt, H. M., Pelzel, H. R., Schlamp, C. L., & Nickells, R. W. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-39 · Cited by 86
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
He, R., Chen, Y., Chen, Y., Ougolkov, A. V., Zhang, J.-S., Savoy, D. N., Billadeau, D. D., & Kozikowski, A. P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901667k · Cited by 66
Self-citationThe Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, F., Zwinderman, M., & Dekker, F. (2018) · Molecules · doi:10.3390/molecules23030551 · Cited by 66
Pulya, S., Himaja, A., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00614 · Cited by 66
Explorative Study on Isoform-Selective Histone Deacetylase Inhibitors
Suzuki, T. (2009) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.57.897 · Cited by 63
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
Wilson, A. J., Holson, E. B., Wagner, F. F., Zhang, Y.-L., Fass, D. M., Haggarty, S. J., Bhaskara, S., Hiebert, S. W., Schreiber, S. L., & Khabele, D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.6.15956 · Cited by 58
Choong, C., Sasaki, T., Hayakawa, H., Yasuda, T., Baba, K., Hirata, Y., Uesato, S., & Mochizuki, H. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.001 · Cited by 56
Epigenetic mechanisms governing the process of neurodegeneration
Qureshi, I., & Mehler, M. F. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.011 · Cited by 47
Amin, S. A., Adhikari, N., Kotagiri, S., Jha, T., & Ghosh, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.077 · Cited by 42
Therapeutic Potential of Isoform Selective Hdac Inhibitors for the Treatment of Schizophrenia
Weïwer, M., Lewis, M. C., Wagner, F. F., & Holson, E. B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.141 · Cited by 46
The Biology and Therapeutic Implications of HDACs in the Heart
McKinsey, T. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_4 · Cited by 41
Ibrahim, T. S., Sheha, T. A., Abo-Dya, N. E., AlAwadh, M. A., Alhakamy, N. A., Abdel‐Samii, Z. K., Panda, S. S., Abuo‐Rahma, G. E. A., & Mohamed, M. F. A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103797 · Cited by 41
Routholla, G., Pulya, S., Patel, T., Abdul Amin, S., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105050 · Cited by 39
Synthesis and Biological Evaluation of C7‐Demethyl Largazole Analogues
Chen, F., Gao, A., Li, J. X., & Nan, F. (2009) · ChemMedChem · doi:10.1002/cmdc.200900125 · Cited by 39
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)
Bourguet, E., Ozdarska, K., Moroy, G., Jeanblanc, J., & Naassila, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00115 · Cited by 36
Stratton, M. S., & McKinsey, T. A. (2014) · Biochemistry and Cell Biology · doi:10.1139/bcb-2014-0119 · Cited by 33
Cavasin, M. A., Stenmark, K. R., & McKinsey, T. A. (2015) · Pulmonary Circulation · doi:10.1086/679700 · Cited by 33
Development of Histone Deacetylase Inhibitors as Therapeutics for Neurological Disease
Gottesfeld, J. M., & Pandolfo, M. (2009) · Future Neurology · doi:10.2217/fnl.09.55 · Cited by 32
Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease
Tan, Y., Delvaux, E., Nolz, J., Coleman, P. D., Chen, S., & Mastroeni, D. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.018 · Cited by 32
Traore, M. D. M., Zwick, V., Simões‐Pires, C. A., Nurisso, A., Issa, M. E., Cuendet, M., Maynadier, M., Wein, S., Vial, H. J., Jamet, H., et al. (2017) · ACS Omega · doi:10.1021/acsomega.6b00481 · Cited by 31
Designing potential HDAC3 inhibitors to improve memory and learning
Amin, S. A., Adhikari, N., Jha, T., & Ghosh, B. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1477625 · Cited by 28
Farag, A., Ewida, H. A., & Ahmed, M. S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.011 · Cited by 27
Creating zinc monkey wrenches in the treatment of epigenetic disorders
Kalin, J. H., Butler, K. V., & Kozikowski, A. P. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.007 · Cited by 21
Self-citationMedicinal chemistry advances in targeting class I histone deacetylases
Abdallah, D. I., de Araujo, E. D., Patel, N. H., Hasan, L. S., Moriggl, R., Krämer, O. H., & Gunning, P. T. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00166 · Cited by 17
“Further reaffirming the N-heterocycle trend observed with HDAC3 selective inhibitors, both T326 and compound 2 bear triazole functionalities [72, 73].”
BackgroundInfluentialDevelopment of second generation epigenetic agents
JONES, P. G. (2011) · MedChemComm · doi:10.1039/c1md00199j · Cited by 17
Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
Garmpis, N., Damaskos, C., Garmpi, A., Valsami, S. I., & Dimitroulis, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00013-9 · Cited by 9
Epigenetic Targets and Cancer Drug Discovery
Woster, P. M. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45015-0 · Cited by 3
Podili, R., Mishra, K. A., Akkewar, A. S., Kumar, S., Rayala, V. V. S. P. K., Kulhari, U., Sahu, B. D., Radhakrishnanand, P., & Sethi, K. K. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23591 · Cited by 2
Synthesis and Biological Evaluation of C7‐Demethyl Largazole Analogues
Chen, F., Gao, A., Li, J. X., & Nan, F. (2009) · ChemMedChem · doi:10.1002/cmdc.200990038 · Cited by 2
The Role of Histone Deacetylases in Cytokine Regulation in Human Gestational Tissues
Munro, S. K. (2013) · ResearchSpace (University of Auckland) · Cited by 2
Traore, M. D. M. (2016) · theses.fr (ABES) · doi:10.70675/adea84c8z9c7az4f8dz8710z31e35c676057 · Cited by 2
Li, T., Hua, K., Sheng, X., Liu, L., Tan, J., Wang, L., Wei, B., Ji, H., & Zhang, Y. (2014) · Biomedical Chromatography · doi:10.1002/bmc.3209 · Cited by 1
Deposition of Foreign Proteins in Plant Vacuoles: A Unique Characteristic of Plant-Based Platforms
Petruccelli, S. (2019) · Conicet · Cited by 1
Evaluation of Photoreactive and Phenothiazine-based HDAC Inhibitors
Madriaga, A. (2014) · Figshare
TARGETING THE CLASS I HDACS TO DISRUPT QUIESCENT HIV-1 PROVIRUSES
Barton, K. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/8kp5-4d50
[Histone deacetylase 6: structure, functions and development of selective inhibitors].
Liu, R., & Fang, H. (2015) · PubMed
HDAC inhibitors from natural and synthetic libraries: towards the development of biochemical probes
Zwick, V. (2016) · Archive ouverte UNIGE (University of Geneva) · doi:10.13097/archive-ouverte/unige:88976
Synthèses d’inhibiteurs de HDAC et leurs tests biologiques (Cytotoxicité, HDAC inhibition)
Ozdarska, K. (2020) · theses.fr (ABES) · doi:10.70675/9f872011z7544z4b35z8e5ezcf4812094c2e
BindingDB Entry 50018471: Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
BindingDB (2024) · UC San Diego · doi:10.7270/q2tt4w4d
BindingDB (2014) · UC San Diego · doi:10.7270/q29g5p7j
Acute kidney injury in zebrafish larvae as a regeneration model for drug discovery
Skvarca, L. B. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Metadata
- Authors
- Chen, Y., He, R., Chen, Y., D'Annibale, M. A., Langley, B., & Kozikowski, A. P.
- Affiliations
- University of Illinois Chicago (US)
- Cornell University (US)
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2009-05-04
- Volume
- 4
- Issue
- 5
- Pages
- 842-852
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W1996377862
- Cited by
- 51
- References
- 43
- Citations by year
- 2024: 1 · 2023: 4 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 6 · 2017: 2 · 2015: 6 · 2014: 4 · 2013: 5 · 2012: 1
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ChemMedChem (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Drug Discovery Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- histone deacetylase inhibitors, zinc-binding groups, oxidative stress, neuronal cell death, neuroprotection, cortical neurons, homocysteic acid, HDAC6, thioesters, disulfides, neurodegenerative diseases
- MeSH terms
- Animals, Benzamides, Carrier Proteins, Cells, Cultured, Enzyme Inhibitors, Histone Deacetylases, Hydroxamic Acids, Models, Biological, Neurons, Sulfhydryl Compounds, Rats, Sprague-Dawley, Apoptosis, Oxidative Stress, Neuroprotective Agents, Protein Isoforms, Rats, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.